Literature DB >> 22024080

Plasma fibrinogen-like protein 2 levels in patients with non-alcoholic fatty liver disease.

Yasar Colak1, Ebubekir Senates, Oguzhan Ozturk, Yusuf Yilmaz, Ender Coskunpinar, Ozlem Timirci Kahraman, Onder Sahin, Ebru Zemheri, Feruze Yilmaz Enc, Celal Ulasoglu, Safak Kiziltas, Oya Ovunc Kurdas, Ilyas Tuncer.   

Abstract

BACKGROUND/AIMS: Fibrinogen-like protein 2 (fgl2), has recently been identified as a new member of the fibrinogen-like family of proteins. In this study we assayed plasma levels of fgl2 in patients with biopsy proven non-alcoholic fatty liver disease (NAFLD) and examined their association with clinical, biochemical and histological phenotypes.
METHODOLOGY: Levels of plasma fgl2 were measured by enzyme linked immunosorbent assay and compared between the study groups. Moreover, concentrations of fgl2 were assessed in relation to the general characteristics of the study participants and the results of the liver biopsy.
RESULTS: Levels of fgl2 were significantly higher in patients with definite non-alcoholic steatohepatitis (NASH) (788±190pg/mL, p<0.001) and borderline NASH (710 ± 140pg/mL, p<0.001) compared with controls (515±174pg/mL). No significant differences were found in patients with simple steatosis (649 ± 162pg/mL) as compared with controls. There were no associations between the plasma fgl2 levels with the fibrosis stage and steatosis grade.
CONCLUSIONS: Although subject to future confirmation, our data suggest that fgl2 levels are elevated in the more severe forms of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024080     DOI: 10.5754/hge11248

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Physiological functions and clinical implications of fibrinogen-like 2: A review.

Authors:  Genyan Yang; W Craig Hooper
Journal:  World J Clin Infect Dis       Date:  2013-08-25

Review 2.  Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease.

Authors:  Ekta Pandey; Aiah S Nour; Edward N Harris
Journal:  Front Physiol       Date:  2020-07-21       Impact factor: 4.566

Review 3.  Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation.

Authors:  Xin-Guang Liu; Yu Liu; Feng Chen
Journal:  Oncotarget       Date:  2017-01-10

4.  Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases.

Authors:  Hoang Van Tong; Nguyen Van Ba; Nghiem Xuan Hoan; Mai Thanh Binh; Dao Thanh Quyen; Ho Anh Son; Hoang Van Luong; Do Quyet; Christian G Meyer; Le Huu Song; Nguyen Linh Toan; Thirumalaisamy P Velavan
Journal:  BMC Infect Dis       Date:  2018-11-12       Impact factor: 3.090

5.  Fc gamma RIIb expression levels in human liver sinusoidal endothelial cells during progression of non-alcoholic fatty liver disease.

Authors:  Tomoko Ishikawa; Hiroshi Yokoyama; Tomokazu Matsuura; Yoko Fujiwara
Journal:  PLoS One       Date:  2019-01-29       Impact factor: 3.240

6.  Stat4 rs7574865 polymorphism promotes the occurrence and progression of hepatocellular carcinoma via the Stat4/CYP2E1/FGL2 pathway.

Authors:  Caie Wang; Na Gao; Lukui Yang; Yuanyuan Guo; Yan Fang; Tong Wang; Chen Xu; Gui Fang Li; Jun Zhou; Yunfei Zhang; Qiang Wen; Hailing Qiao
Journal:  Cell Death Dis       Date:  2022-02-08       Impact factor: 9.685

7.  Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.

Authors:  Junjian Hu; Hongwu Wang; Xitang Li; Yonggang Liu; Yuqiang Mi; Hongyan Kong; Dong Xi; Weiming Yan; Xiaoping Luo; Qin Ning; Xiaojing Wang
Journal:  Theranostics       Date:  2020-08-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.